{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:34:33Z","timestamp":1793172873190,"version":"4.5.0"},"reference-count":160,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Disease Overview<\/jats:title>\n                    <jats:p>Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1\u20132 cases per 100\u2009000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis<\/jats:title>\n                    <jats:p>\n                      CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (\n                      <jats:italic>ABL1<\/jats:italic>\n                      ) from chromosome 9q34 with the breakpoint cluster region (\n                      <jats:italic>BCR<\/jats:italic>\n                      ) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Frontline Therapy<\/jats:title>\n                    <jats:p>Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first\u2010line treatment of newly diagnosed CML in chronic phase (CML\u2010CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Salvage Therapy<\/jats:title>\n                    <jats:p>\n                      For CML post failure on frontline therapy, second\u2010line options include second and third generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      mutational status. Patients who develop the T315I \u201cgatekeeper\u201d mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML\u2010CP and failure (due to resistance) of at least two TKIs, and for all patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on all TKIs can maintain long\u2010term survival if they continue a daily most effective\/least toxic TKI, with or without the addition of non\u2010TKI anti\u2010CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan and others).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ajh.26642","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T11:53:36Z","timestamp":1656158016000},"page":"1236-1256","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas M. D. Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas M. D. Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"e_1_2_16_2_1","volume-title":"Cancer Facts and Figures","author":"Society AC","year":"2021"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1838.1838"},{"issue":"11","key":"e_1_2_16_6_1","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto\u2010oncogene Raf\u20101","volume":"22","author":"Okuda K","year":"1994","journal-title":"Exp Hematol"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11746"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90241-4"},{"issue":"2","key":"e_1_2_16_9_1","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR\u2010ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai K","year":"1996","journal-title":"Oncogene"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.811"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.49.31704"},{"issue":"5","key":"e_1_2_16_12_1","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1816"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23427"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110189"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402329"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690230"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24748"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.006"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2545"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.253"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.517.517"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7051"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31357"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32504"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152614"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00333-1"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70201-7"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01111-2"},{"issue":"1","key":"e_1_2_16_49_1","first-page":"665","article-title":"Gene expression signature predicts deep molecular response (DMR) in chronic myeloid leukemia (CML): an exploratory biomarker analysis from ENESTnd","volume":"134","author":"Druker BJ","year":"2019","journal-title":"Blood"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-601674"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137393"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00021-6"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32623"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32627"},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134168"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3373"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1180"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11543"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25939"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.001"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30139-X"},{"issue":"5","key":"e_1_2_16_66_1","first-page":"287","article-title":"Insights into the increasing costs of cancer drugs","volume":"17","author":"Bach PB","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1024"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30545"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.01.014"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30087-0"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000745"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.2284"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-680058"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_16_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_2_16_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-229864"},{"key":"e_1_2_16_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9176"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"e_1_2_16_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6999"},{"key":"e_1_2_16_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_16_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0805-1"},{"key":"e_1_2_16_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490128"},{"key":"e_1_2_16_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466037"},{"key":"e_1_2_16_85_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090282"},{"key":"e_1_2_16_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-566323"},{"key":"e_1_2_16_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0693"},{"key":"e_1_2_16_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143023"},{"key":"e_1_2_16_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.006"},{"key":"e_1_2_16_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30167-3"},{"key":"e_1_2_16_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.247"},{"key":"e_1_2_16_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_2_16_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_16_94_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"e_1_2_16_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_16_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7549"},{"key":"e_1_2_16_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.181"},{"key":"e_1_2_16_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_16_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_16_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_16_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3780.3780"},{"key":"e_1_2_16_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.2765.2765"},{"key":"e_1_2_16_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_16_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.451.451"},{"key":"e_1_2_16_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24325"},{"key":"e_1_2_16_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0915-9"},{"issue":"1","key":"e_1_2_16_107_1","first-page":"496","article-title":"Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first\u2010line tyrosine kinase inhibitors","volume":"134","author":"Rosti G","year":"2019","journal-title":"Blood"},{"key":"e_1_2_16_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_16_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2010.01054.x"},{"key":"e_1_2_16_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_16_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"e_1_2_16_112_1","unstructured":"Cambridge MAP Inc.Iclusig (ponatinib) [prescribing information]2014."},{"key":"e_1_2_16_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012082"},{"key":"e_1_2_16_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146175"},{"key":"e_1_2_16_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845672.11934.a4"},{"key":"e_1_2_16_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_2_16_117_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_2_16_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_2_16_119_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843512.62237.dc"},{"key":"e_1_2_16_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139677"},{"key":"e_1_2_16_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845732.28959.a9"},{"key":"e_1_2_16_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845708.96602.91"},{"key":"e_1_2_16_123_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845716.75856.2d"},{"key":"e_1_2_16_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845720.69342.77"},{"key":"e_1_2_16_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142954"},{"issue":"1","key":"e_1_2_16_126_1","first-page":"493","article-title":"An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd generation of BCR\u2010ABL tyrosine kinase inhibitor (TKI), in patients with TKI resistant chronic myeloid leukemia","volume":"134","author":"Zhai Y","year":"2019","journal-title":"Blood"},{"key":"e_1_2_16_127_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153065"},{"key":"e_1_2_16_128_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"e_1_2_16_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25717"},{"key":"e_1_2_16_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_16_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_2_16_132_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302679"},{"key":"e_1_2_16_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30558"},{"key":"e_1_2_16_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141689"},{"key":"e_1_2_16_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.90"},{"key":"e_1_2_16_136_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0218"},{"key":"e_1_2_16_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.001"},{"key":"e_1_2_16_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26550"},{"key":"e_1_2_16_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_16_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_16_141_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_16_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2604-x"},{"key":"e_1_2_16_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"issue":"1","key":"e_1_2_16_144_1","first-page":"27","article-title":"A report on 114 patients who experienced treatment free remission in a single institution during a 15\u2009years period: long term follow\u2010up, late molecular relapses and second attempts","volume":"134","author":"Spentchian M","year":"2019","journal-title":"Blood"},{"key":"e_1_2_16_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-696013"},{"key":"e_1_2_16_146_1","doi-asserted-by":"publisher","DOI":"10.2174\/15680096113139990086"},{"key":"e_1_2_16_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545640"},{"key":"e_1_2_16_148_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1925"},{"key":"e_1_2_16_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.10.013"},{"key":"e_1_2_16_150_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_2_16_151_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.323"},{"key":"e_1_2_16_152_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22778"},{"key":"e_1_2_16_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031682"},{"key":"e_1_2_16_154_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019836"},{"key":"e_1_2_16_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.08.008"},{"key":"e_1_2_16_156_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28433"},{"key":"e_1_2_16_157_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30864"},{"key":"e_1_2_16_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00370-7"},{"key":"e_1_2_16_159_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832253"},{"key":"e_1_2_16_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23097-w"},{"key":"e_1_2_16_161_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200220"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:56:06Z","timestamp":1692759366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":160,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/ajh.26642"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26642","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"2022-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}